ALLO-715
ALLO-715-101
Phase 1 gene_therapy completed
Quick answer
ALLO-715 for Relapsed/Refractory Multiple Myeloma is a Phase 1 program (gene_therapy) at Allogene Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Allogene Therapeutics
- Indication
- Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1
- Modality
- gene_therapy
- Status
- completed